Search Patents
  • Patent number: 5177190
    Abstract: A method is disclosed for isolating and purifying C5a receptor from human polymorphonuclear leukocytes. C5a is a complement-derived protein which is important as a mediator of inflammatory responses. C5a receptor may be used to screen create and quantify C5a antagonists useful as anti-inflammatory agents and immunoregulants and to generate monoclonal and polyclonal anti-C5a receptor antibodies useful as anti-inflammatory agents and immunoregulants.
    Type: Grant
    Filed: January 22, 1992
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Thomas E. Rollins, Martin S. Springer
  • Patent number: 5196516
    Abstract: The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment coding for such a polypeptide also form part of the present invention.
    Type: Grant
    Filed: July 21, 1989
    Date of Patent: March 23, 1993
    Assignee: Akzo N.V.
    Inventors: Christa S. Schreurs, Thomas C. Mettenleiter, Artur J. Simon, Noemi Lukacs, Hanns J. Rziha
  • Patent number: 5273744
    Abstract: This invention relates to the development of a vaccine against Theileria parva, which is a protozoan parasite infecting cattle in Africa. The invention specifically relates to the use of the 67 kDa glycoprotein from the surface of the T. parva sporozoite as an immunogen for inducing immunoprotection against T. parva in bovine species. This 67 kDa antigen is produced using recombinant genetics. Plasmids containing nucleic acid segments encoding the antigen, host cells containing the nucleic acid segments and recombinant methods for producing the antigen are part of this invention.
    Type: Grant
    Filed: February 11, 1992
    Date of Patent: December 28, 1993
    Assignee: International Laboratory for Research on Animal Diseases
    Inventors: Anthony J. Musoke, Vish Nene, Keith Iams, Vinand M. Nantulya
  • Patent number: 4981951
    Abstract: A method of purifying a recombinant protein from a solution, such as tissue culture fluid, containing gylcoproteins. The affinity of lectins for specific glycoproteins is assessed and used to select a particular lectin specific for the contaminating glycoprotein(s). A sugar buffer such as alpha methyl mannoside prevents binding of the recombinant protein. The preferred lectin is lentil lectin, for use in separating recombinant Factor VIII from tissue culture fluid contaminated with rodent protein from the cell line used to produce the recombinant Factor VIII.
    Type: Grant
    Filed: April 14, 1988
    Date of Patent: January 1, 1991
    Assignee: Miles Inc.
    Inventor: Grace C. Tsay
  • Patent number: 5021554
    Abstract: The particle size of amorphous protein material is reduced to uniform particulates without protein decomposition or loss of activity by passing the material through a fluid-energy mill.
    Type: Grant
    Filed: February 24, 1989
    Date of Patent: June 4, 1991
    Assignee: Eli Lilly and Company
    Inventor: William W. Thompson
  • Patent number: 5504194
    Abstract: A lymphoid cell line cDNA that encodes an adhesion receptor for high endothelial venules (HEV).
    Type: Grant
    Filed: May 15, 1992
    Date of Patent: April 2, 1996
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Thomas P. St. John, W. Michael Gallatin, Rejean L. Idzerda
  • Patent number: 5141743
    Abstract: The present invention relates to a method for isolating and purifying transferrin and lactoferrin receptor proteins from bacterial pathogens by affinity chromatography and to vaccine antigens containing the purified receptor proteins.
    Type: Grant
    Filed: January 10, 1991
    Date of Patent: August 25, 1992
    Assignee: University Technologies International, Inc.
    Inventor: Anthony B. Schryvers
  • Patent number: 5198423
    Abstract: This invention relates to a functional polypeptide containing the binding domain of human fibronectin and the heparin-binding domain of human fibronectin.
    Type: Grant
    Filed: May 22, 1990
    Date of Patent: March 30, 1993
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Yuki Taguchi, Yoh'ichi Ohdate, Yasutoshi Kawase, Shouichi Goto, Fusao Kimizuka, Ikunoshin Kato, Ikuo Saiki, Ichiro Azuma
  • Patent number: 5116952
    Abstract: Substantially pure proteins active in humoral hypercalcemia of malignancy (PTHrP) and sub-units and fragments thereof. Antibody reagents capable of binding to epitopes of PTHrP. Methods and kits for the detection of PTHrP.
    Type: Grant
    Filed: May 9, 1988
    Date of Patent: May 26, 1992
    Assignee: The University of Melbourne
    Inventors: Thomas J. Martin, Jane M. Moseley, Bruce E. Kemp, Richard E. H. Wettenhall
  • Patent number: 5717067
    Abstract: A new substrate of epidermal growth factor receptor and certain other tyrosine kinase receptors denominated eps15, polynucleotides encoding epsl5, antisense eps15 polynucleotide, triple helix eps15 polynucleotide, antibodies to eps15, and assays for determining eps15.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Pier Paolo DiFiore, Francesca Fazioli
  • Patent number: 5037959
    Abstract: A class of proteins associated with self-incompatibility alleles of plants, preferably of gametophytic self-incompatibility type, are provided. These proteins inhibit pollen tube growth in a plant style having the associated self-incompatibility allele, and have defined amino acid homologies and cross-reactivities.
    Type: Grant
    Filed: May 15, 1987
    Date of Patent: August 6, 1991
    Assignee: Lubrizol Genetics, Inc.
    Inventors: Adrienne E. Clarke, Elizabeth G. Williams, Marilyn A. Anderson, Shaio-Lim Mau, Rosslyn Hoggart, Edwina Cornish
  • Patent number: 5095094
    Abstract: The proteins of the invention are specifically recognized by polyclonal anti-AC antibodies raised against purified AC preparations, devoid of adenylate cyclase CaM-activable activity and devoid of affinity for CaM.
    Type: Grant
    Filed: February 20, 1990
    Date of Patent: March 10, 1992
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Colette Brezin, Hoang-Oanh Nghiem, Jean Luc Boucaud, Jean M. Alonso
  • Patent number: 5279958
    Abstract: A protein characterized by the fact that it is a non-keratinic protein present on the apicolateral surface and absent on the basal surface of basal epidermal cells, in particular in man, that it is present in a nonpolarized manner in basocellular and spinocellular carcinomas and absent in melanoma and naevus cells; antibodies directed against said protein, their preparation and their use as reagents; cellular stocks secreting such antibodies, and their preparation.
    Type: Grant
    Filed: October 30, 1987
    Date of Patent: January 18, 1994
    Assignee: Dermatologiques (CIRD)
    Inventors: Bruno Bernard, Yves Darmon
  • Patent number: 5179198
    Abstract: The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement-mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.
    Type: Grant
    Filed: July 7, 1989
    Date of Patent: January 12, 1993
    Assignees: Hidechika Okada, Mitsubishi Corporation
    Inventors: Hidechika Okada, Noriko Okada, Yoichi Nagami, Kazuhiro Takahashi, Hisao Takizawa, Jun Kondo
  • Patent number: 5521296
    Abstract: The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement-mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.
    Type: Grant
    Filed: August 1, 1991
    Date of Patent: May 28, 1996
    Assignees: Hidechika Okada, Mitsubishi Kasei Corp.
    Inventors: Hidechika Okada, Noriko Okada, Yoichi Nagami, Kazuhiro Takahashi, Hisao Takizawa, Jun Kondo
  • Patent number: 5206347
    Abstract: A method of isolating cell surface receptors utilizing a short peptide sequence bound to an affinity column. Cell surface receptors which bind selectively to the short peptide and which are specific to various adhesion proteins may be isolated therewith from various cell preparations. These receptors, whose functional integrity has been maintained by the presence of the peptide ligand, are incorporated into liposomes and used to deliver specific compounds inside the liposomes to select tissues containing the specific adhesion proteins.
    Type: Grant
    Filed: July 13, 1990
    Date of Patent: April 27, 1993
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Michael D. Pierschbacher
  • Patent number: 5128449
    Abstract: The present invention provides for a new polypeptide and a method for producing the same. The polypeptide has a molecular weight of approximately 30,000 daltons as a dimer and a monomer molecular weight of about 15,000 daltons, an isoelectric pH of about 4.47 and an activity of at least 21,000 units per milligram of protein in the monomer or dimer state. The preferred method comprises chromatographing a crude polypeptide-containing medium on a dextran derived chromatography column; precipitating the eluate in a water-ethanol solution; electrophoresing the precipitate in a polyacrylamide gel; and chromatographing the extract on a reverse phase-high performance liquid chromatography column.
    Type: Grant
    Filed: July 5, 1988
    Date of Patent: July 7, 1992
    Assignee: The University of Tennessee Research Corporation
    Inventor: Ted P. McDonald
  • Patent number: 5101014
    Abstract: The present invention comprises a method for the purification of the 69 kDa outer membrane protein of Bordetella B. pertussis and the protein purified therewith. A preferred embodiment comprises the purification of the 69 kDa protein from Bordetella B. pertussis strain Bp 353. The present process is advantageous in that it does not require or involve the use of biologics (such as monoclonal antibodies) and therefore simplifies the purification procedure and makes the resulting purified protein particularly advantageous for inclusion in acellular vaccines.
    Type: Grant
    Filed: February 10, 1989
    Date of Patent: March 31, 1992
    Assignee: United States of America
    Inventors: Drusilla L. Burns, Michael J. Brennan, Jeanine L. Gould-Kostka, Charles R. Manclark
  • Patent number: 5462863
    Abstract: A method for recovering hepatitis B surface antigen protein from transformed yeast cells including the steps of (i) obtaining an aqueous homogenate of the yeast cells; (ii) enriching the hepatitis B surface antigen protein in the homogenate with a protein-aggregating reagent to form a precipitate which contains hepatitis B surface antigen protein; (iii) dissolving the precipitate in a buffer to form a suspension; and (iv) post-homogenizing the suspension to obtain a 10% to 50% increase in yield of the hepatitis B surface antigen protein as calculated based on a yield achieved without performing the post-homogenizing step.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: October 31, 1995
    Assignee: Development Center for Biotechnology
    Inventors: Jih-Han Hsieh, Shu-Ching Shih, Wei-Kuang Chi, Yi-Ding Chu, Ae-Ning Lin
  • Patent number: 5169936
    Abstract: A process for the purification of proteins from solutions containing contaminants of similar net charge and molecular weight is provided, comprising contacting a solution containing the desired protein with an immobilized metal affinity chromatography resin in a buffer containing a low concentration of a weak ligand for the chelant of the resin. The adsorbed protein is then eluted using a buffer having a high concentration of the same weak ligand, e.g., Tris. Particularly preferred features employ agarose-iminodiacetic acid resins having copper cations and are especially useful in obtaining preparations of homogeneous, stable rsT4 proteins.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: December 8, 1992
    Assignee: Biogen, Inc.
    Inventors: Mark A. Staples, Christopher A. Pargellis